Acute Myeloid Leukemia

New Diagnosis

IRB# 16142 Phase 1 treatment with AG-120

IRB#7195 Phase 2 Kinase Inhibition using a Comprehensive In Vitro Inhibitor panel to select individualized targeted therapies

IRB#10674 Phase 3, Randomized quizartinib monotherapy vs salvage chemotherapy

IRB#15601 Phase 1 Study of IMGN779 Administered Intravenously

Relapsed/Refractory

FLT3-ITD +

CD33 +

IRB#11076 Phase I using APT-253 in dose escalation

IRB#11076 Phase I using APT-253 in dose escalation

IRB#15214 Phase 1a/1b study of oral INCB052793 (jak1/jak2 inhibitor)

IRB#15953 Phase 2 treatment with SY-1425

IRB#11766 Study Phase Ib combination standard induction plus a targeted therapy with a kinase inhibitor based on drug sensitivity

IRB# 15467 S0919: Ph2 Idarubicin AraC in combination with Pravastatin for Poor Risk AML

IRB# 15903 Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

IRB# 16492 LLS – S1 Targeting CD200 with Samalizumab in Elderly Untreated Core Binding Factor AML

IRB# 16429 Study coming soon

IRB# 16493 LLS – S2 Phase Ib/II of BI836858 with Azacitidine Elderly untreated AML

IRB# 15953 Phase 2 Treatment with SY1425

IRB#11501 Study coming soon (HLA-A2.01 and PRAME)

IRB#16142 Phase 1 treatment with AG-120

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

1/4/2017 www.ohsu.edu/cancer